How I treat steroid-refractory acute graft-versus-host disease

Steroid-resistant or steroid-refractory acute graft-versus-host disease (SR-aGVHD) poses one of the most vexing challenges faced by providers who care for patients after allogeneic hematopoietic cell transplantation. For the past 4 decades, research in the field has been driven by the premise that p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2020-05, Vol.135 (19), p.1630-1638
1. Verfasser: Martin, Paul J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1638
container_issue 19
container_start_page 1630
container_title Blood
container_volume 135
creator Martin, Paul J.
description Steroid-resistant or steroid-refractory acute graft-versus-host disease (SR-aGVHD) poses one of the most vexing challenges faced by providers who care for patients after allogeneic hematopoietic cell transplantation. For the past 4 decades, research in the field has been driven by the premise that persistent graft-versus-host disease (GVHD) results from inadequate immunosuppression. Accordingly, most efforts to solve this problem have relied on retrospective or prospective studies testing agents that have direct or indirect immunosuppressive effects. Retrospective studies far outnumber prospective studies, and no controlled prospective trial has shown superior results for any agent over others. Truth be told, I do not know how to treat SR-aGVHD. Preclinical work during the past decade has provided fresh insights into the pathogenesis of acute GVHD, and translation of these insights toward development of more effective treatments for patients with SR-aGVHD has at last begun. Given the limited state of current knowledge, this “How I Treat” review highlights the overriding imperative to avoid harm in caring for patients with SR-aGVHD. Prospective trials that are widely available are urgently needed to advance the field. [Display omitted]
doi_str_mv 10.1182/blood.2019000960
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2381843047</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120620444</els_id><sourcerecordid>2381843047</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-52b4065b6920e270949881c365305efb359a98a34507f1566e029ab439712c0f3</originalsourceid><addsrcrecordid>eNp1kDFPwzAQRi0EoqWwM6GMLC5nO05iBiRUAa1UiQVmy3EuYNTWxXaK-u8JtMDEdNLpfZ_uHiHnDMaMVfyqXnjfjDkwBQCqgAMyZJJXFIDDIRn2y4LmqmQDchLjGwDLBZfHZCA4B14IGJKbqf_IZlkKaFIWEwbvGhqwDcYmH7aZsV3C7CWYNtENhthF-upjyhoX0UQ8JUetWUQ8288Reb6_e5pM6fzxYTa5nVMrQSYqeZ1DIetCcUBegspVVTErCilAYlsLqYyqjMgllC2TRYHAlalz0d_OLbRiRC53vevg3zuMSS9dtLhYmBX6LmouKlblAvKyR2GH2uBj7F_R6-CWJmw1A_1lTX9b03_W-sjFvr2rl9j8Bn409cD1DsD-x43DoKN1uLLYuIA26ca7_9s_AaEXeh0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2381843047</pqid></control><display><type>article</type><title>How I treat steroid-refractory acute graft-versus-host disease</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Martin, Paul J.</creator><creatorcontrib>Martin, Paul J.</creatorcontrib><description>Steroid-resistant or steroid-refractory acute graft-versus-host disease (SR-aGVHD) poses one of the most vexing challenges faced by providers who care for patients after allogeneic hematopoietic cell transplantation. For the past 4 decades, research in the field has been driven by the premise that persistent graft-versus-host disease (GVHD) results from inadequate immunosuppression. Accordingly, most efforts to solve this problem have relied on retrospective or prospective studies testing agents that have direct or indirect immunosuppressive effects. Retrospective studies far outnumber prospective studies, and no controlled prospective trial has shown superior results for any agent over others. Truth be told, I do not know how to treat SR-aGVHD. Preclinical work during the past decade has provided fresh insights into the pathogenesis of acute GVHD, and translation of these insights toward development of more effective treatments for patients with SR-aGVHD has at last begun. Given the limited state of current knowledge, this “How I Treat” review highlights the overriding imperative to avoid harm in caring for patients with SR-aGVHD. Prospective trials that are widely available are urgently needed to advance the field. [Display omitted]</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.2019000960</identifier><identifier>PMID: 32202630</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Drug Resistance, Neoplasm - drug effects ; Graft vs Host Disease - drug therapy ; Graft vs Host Disease - etiology ; Graft vs Host Disease - pathology ; Hematologic Diseases - pathology ; Hematologic Diseases - therapy ; Hematopoietic Stem Cell Transplantation - adverse effects ; Humans ; Immunosuppressive Agents - therapeutic use ; Male ; Prognosis ; Remission Induction ; Salvage Therapy ; Steroids - pharmacology</subject><ispartof>Blood, 2020-05, Vol.135 (19), p.1630-1638</ispartof><rights>2020 American Society of Hematology</rights><rights>2020 by The American Society of Hematology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-52b4065b6920e270949881c365305efb359a98a34507f1566e029ab439712c0f3</citedby><cites>FETCH-LOGICAL-c505t-52b4065b6920e270949881c365305efb359a98a34507f1566e029ab439712c0f3</cites><orcidid>0000-0001-9051-1215</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32202630$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martin, Paul J.</creatorcontrib><title>How I treat steroid-refractory acute graft-versus-host disease</title><title>Blood</title><addtitle>Blood</addtitle><description>Steroid-resistant or steroid-refractory acute graft-versus-host disease (SR-aGVHD) poses one of the most vexing challenges faced by providers who care for patients after allogeneic hematopoietic cell transplantation. For the past 4 decades, research in the field has been driven by the premise that persistent graft-versus-host disease (GVHD) results from inadequate immunosuppression. Accordingly, most efforts to solve this problem have relied on retrospective or prospective studies testing agents that have direct or indirect immunosuppressive effects. Retrospective studies far outnumber prospective studies, and no controlled prospective trial has shown superior results for any agent over others. Truth be told, I do not know how to treat SR-aGVHD. Preclinical work during the past decade has provided fresh insights into the pathogenesis of acute GVHD, and translation of these insights toward development of more effective treatments for patients with SR-aGVHD has at last begun. Given the limited state of current knowledge, this “How I Treat” review highlights the overriding imperative to avoid harm in caring for patients with SR-aGVHD. Prospective trials that are widely available are urgently needed to advance the field. [Display omitted]</description><subject>Adult</subject><subject>Drug Resistance, Neoplasm - drug effects</subject><subject>Graft vs Host Disease - drug therapy</subject><subject>Graft vs Host Disease - etiology</subject><subject>Graft vs Host Disease - pathology</subject><subject>Hematologic Diseases - pathology</subject><subject>Hematologic Diseases - therapy</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Male</subject><subject>Prognosis</subject><subject>Remission Induction</subject><subject>Salvage Therapy</subject><subject>Steroids - pharmacology</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kDFPwzAQRi0EoqWwM6GMLC5nO05iBiRUAa1UiQVmy3EuYNTWxXaK-u8JtMDEdNLpfZ_uHiHnDMaMVfyqXnjfjDkwBQCqgAMyZJJXFIDDIRn2y4LmqmQDchLjGwDLBZfHZCA4B14IGJKbqf_IZlkKaFIWEwbvGhqwDcYmH7aZsV3C7CWYNtENhthF-upjyhoX0UQ8JUetWUQ8288Reb6_e5pM6fzxYTa5nVMrQSYqeZ1DIetCcUBegspVVTErCilAYlsLqYyqjMgllC2TRYHAlalz0d_OLbRiRC53vevg3zuMSS9dtLhYmBX6LmouKlblAvKyR2GH2uBj7F_R6-CWJmw1A_1lTX9b03_W-sjFvr2rl9j8Bn409cD1DsD-x43DoKN1uLLYuIA26ca7_9s_AaEXeh0</recordid><startdate>20200507</startdate><enddate>20200507</enddate><creator>Martin, Paul J.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9051-1215</orcidid></search><sort><creationdate>20200507</creationdate><title>How I treat steroid-refractory acute graft-versus-host disease</title><author>Martin, Paul J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-52b4065b6920e270949881c365305efb359a98a34507f1566e029ab439712c0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Drug Resistance, Neoplasm - drug effects</topic><topic>Graft vs Host Disease - drug therapy</topic><topic>Graft vs Host Disease - etiology</topic><topic>Graft vs Host Disease - pathology</topic><topic>Hematologic Diseases - pathology</topic><topic>Hematologic Diseases - therapy</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Male</topic><topic>Prognosis</topic><topic>Remission Induction</topic><topic>Salvage Therapy</topic><topic>Steroids - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martin, Paul J.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martin, Paul J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How I treat steroid-refractory acute graft-versus-host disease</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2020-05-07</date><risdate>2020</risdate><volume>135</volume><issue>19</issue><spage>1630</spage><epage>1638</epage><pages>1630-1638</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Steroid-resistant or steroid-refractory acute graft-versus-host disease (SR-aGVHD) poses one of the most vexing challenges faced by providers who care for patients after allogeneic hematopoietic cell transplantation. For the past 4 decades, research in the field has been driven by the premise that persistent graft-versus-host disease (GVHD) results from inadequate immunosuppression. Accordingly, most efforts to solve this problem have relied on retrospective or prospective studies testing agents that have direct or indirect immunosuppressive effects. Retrospective studies far outnumber prospective studies, and no controlled prospective trial has shown superior results for any agent over others. Truth be told, I do not know how to treat SR-aGVHD. Preclinical work during the past decade has provided fresh insights into the pathogenesis of acute GVHD, and translation of these insights toward development of more effective treatments for patients with SR-aGVHD has at last begun. Given the limited state of current knowledge, this “How I Treat” review highlights the overriding imperative to avoid harm in caring for patients with SR-aGVHD. Prospective trials that are widely available are urgently needed to advance the field. [Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32202630</pmid><doi>10.1182/blood.2019000960</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-9051-1215</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2020-05, Vol.135 (19), p.1630-1638
issn 0006-4971
1528-0020
language eng
recordid cdi_proquest_miscellaneous_2381843047
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Adult
Drug Resistance, Neoplasm - drug effects
Graft vs Host Disease - drug therapy
Graft vs Host Disease - etiology
Graft vs Host Disease - pathology
Hematologic Diseases - pathology
Hematologic Diseases - therapy
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
Immunosuppressive Agents - therapeutic use
Male
Prognosis
Remission Induction
Salvage Therapy
Steroids - pharmacology
title How I treat steroid-refractory acute graft-versus-host disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T01%3A47%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20I%20treat%20steroid-refractory%20acute%20graft-versus-host%20disease&rft.jtitle=Blood&rft.au=Martin,%20Paul%20J.&rft.date=2020-05-07&rft.volume=135&rft.issue=19&rft.spage=1630&rft.epage=1638&rft.pages=1630-1638&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.2019000960&rft_dat=%3Cproquest_cross%3E2381843047%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2381843047&rft_id=info:pmid/32202630&rft_els_id=S0006497120620444&rfr_iscdi=true